Design, synthesis, and biological screening of a series of 4′-fluoro-benzotriazole-acrylonitrile derivatives as microtubule-destabilising agents (MDAs)

References

• Bérubé G. How to utilize academic research efforts in cancer drug discovery. Expert Opin Drug Discov 2019;14:331–4.
   PubMed Web of Science ®Google Scholar
• Giannakakou P, Sackett D, Fojo T. Tubulin/microtubules: still a promising target for new chemotherapeutic agents. J Natl Cancer Inst 2000;92:182–3.
   PubMedGoogle Scholar
• Florian S, Mitchison TJ. Anti-microtubule drugs. Methods Mol Biol 2016;1413:403–21.
   PubMedGoogle Scholar
• Chandrasekaran G, Tátrai P, Gergely F. Hitting the brakes: targeting microtubule motors in cancer. Br J Cancer 2015;113:693–8.
   PubMed Web of Science ®Google Scholar
• Mukhtar E, Adhami VM, Mukhtar H. Targeting microtubules by natural agents for cancer therapy. Mol Cancer Therapeut 2014;13:275–84.
   PubMed Web of Science ®Google Scholar
• Akhmanova A, Steinmetz MO. Control of microtubule organization and dynamics: two ends in the limelight. Nat Rev Mol Cell Biol 2015;16:711–26.
   PubMed Web of Science ®Google Scholar
• Prota AE, Danel F, Bachmann F, et al. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization. J Mol Biol 2014;426:1848–60.
   PubMed Web of Science ®Google Scholar
• Huzil JT, Chen K, Kurgan L, Tuszynski JA. The roles of β-tubulin mutations and isotype expression in acquired drug resistance. Cancer Inf 2007;3:159–81.
   PubMedGoogle Scholar
• Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 2003;8:413–50.
   PubMed Web of Science ®Google Scholar
• Field JJ, Díaz JF, Miller JH. The binding sites of microtubule-stabilizing agents. Chem Biol 2013;20:301–15.
   PubMed Web of Science ®Google Scholar
• Field JJ, Kanakkanthara A, Miller JH. Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function. Bioorg Med Chem 2014;22:5050–9.
   PubMed Web of Science ®Google Scholar
• Markel G, Imazio M, Brucato A, Adler Y. Prevention of recurrent pericarditis with colchicine in 2012. Clin Cardiol 2013;36:125–8.
   PubMed Web of Science ®Google Scholar
• Ter Haar NM, Frenkel J. Treatment of hereditary autoinflammatory diseases. Curr Opin Rheumatol 2014;26:252–8.
   PubMed Web of Science ®Google Scholar
• Cocco G, Chu DCC, Pandolfi S. Colchicine in clinical medicine. A guide for internists. Eur J Intern Med 2010;21:503–8.
   PubMed Web of Science ®Google Scholar
• Andreu JM, Timasheff SN. Conformational states of tubulin liganded to colchicine, tropolone methyl ether, and podophyllotoxin. Biochemistry 1982;21:6465–76.
   PubMed Web of Science ®Google Scholar
• Brossi A, Yeh HJC, Chrzanowska M, et al. Colchicine and its analogues: recent findings. Med Res Rev 1988;8:77–94.
   PubMed Web of Science ®Google Scholar
• Volbracht C, Leist M, Kolb SA, Nicotera P. Apoptosis in caspase-inhibited neurons. Mol Med 2001;7:36–48.
   PubMed Web of Science ®Google Scholar
• Lu Y, Chen J, Xiao M, et al. An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res 2012;29:2943–71.
   PubMed Web of Science ®Google Scholar
• Ravelli RBG, Gigant B, Curmi PA, et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004;428:198–202.
   PubMed Web of Science ®Google Scholar
• Dorléans A, Gigant B, Ravelli RBG, et al. Variations in the colchicine-binding domain provide insight into the structural switch of tubulin. Proc Natl Acad Sci U S A 2009;106:13775–9.
   PubMed Web of Science ®Google Scholar
• Tron GC, Pirali T, Sorba G, et al. Medicinal chemistry of combretastatin A4: present and future directions. ChemInform 2006;49:3033–44.
   Google Scholar
• Seddigi ZS, Malik MS, Saraswati AP, et al. Recent advances in combretastatin based derivatives and prodrugs as antimitotic agents. Medchemcomm 2017;8:1592–603.
   PubMed Web of Science ®Google Scholar
• Carta A, Sanna P, Palomba M, et al. Synthesis and antiproliferative activity of 3-aryl-2-(1H-benzotriazol-1-yl)acrylonitriles. Part III. Eur J Med Chem 2002;37:891–900.
   PubMed Web of Science ®Google Scholar
• Sanna P, Carta A, Nikookar MER. Synthesis and antitubercular activity of 3-aryl substituted-2-(1H(2H) benzotriazol-1(2)-yl)acrylonitriles. Eur J Med Chem 2000;35:535–43.
   PubMed Web of Science ®Google Scholar
• Sanna P, Carta A, Gherardini L, et al. Synthesis and antimycobacterial activity of 3-aryl-, 3-cyclohexyl- and 3-heteroaryl. Il Farmaco 2002;57:79–87.
   PubMedGoogle Scholar
• Carta A, Sanna P, Bacchi A. Synthesis of E/Z 3-(1H-benzotriazol-1-yl-3-(pyridin-4- yl)acrylonitriles and E/Z 2-(3-imino-2-benzofuran-1(3H)- ylidene)acetonitriles. An unusual case of displacement of the benzotriazole ring. Heterocycles 2002;57:1079–90.
   Web of Science ®Google Scholar
• Carta A, Palomba M, Boatto G, et al. Synthesis and antiproliferative activity of 3-aryl-2-[1H(2H)-benzotriazol- 1(2)-yl]acrylonitriles variously substituted: part 4. Farmaco 2004;59:637–44.
   PubMedGoogle Scholar
• Carta A, Briguglio I, Piras S, et al. 3-Aryl-2-[1H-benzotriazol-1-yl]acrylonitriles: a novel class of potent tubulin inhibitors. Eur J Med Chem 2011;46:4151–67.
   PubMed Web of Science ®Google Scholar
• Briguglio I, Laurini E, Pirisi MA, et al. Triazolopyridinyl-acrylonitrile derivatives as antimicrotubule agents: synthesis, in vitro and in silico characterization of antiproliferative activity, inhibition of tubulin polymerization and binding thermodynamics. Eur J Med Chem 2017;141:460–72.
   PubMed Web of Science ®Google Scholar
• Riu F, Sanna L, Ibba R, et al. A comprehensive assessment of a new series of 5′,6′-difluorobenzotriazole-acrylonitrile derivatives as microtubule targeting agents (MTAs). Eur J Med Chem 2021;222:113590.
   PubMed Web of Science ®Google Scholar
• Trott O, Olson AJ. Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010;31:455–61.
   PubMed Web of Science ®Google Scholar
• Berman HM, Battistuz T, Bhat TN, et al. The protein data bank. Acta Crystallogr D Biol Crystallogr 2002;58:899–907.
   PubMed Web of Science ®Google Scholar
• The PyMOL Molecular Graphics System, Version 2.0, Schrödinger, LLC., (n.d.).
   Google Scholar
• Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785–91.
   PubMed Web of Science ®Google Scholar
• Laskowski RA, Swindells MB. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model 2011;51:2778–86.
   PubMed Web of Science ®Google Scholar
• Lai M, Iacono E, Spezia PG, et al. A low-cost simple test for weekly detection of Mycoplasma hyorhinis and arginini contaminations in cell cultures and viral preparations. J Virol Methods 2022;299:114327.
   PubMed Web of Science ®Google Scholar
• Lai M, Amato R, Rocca VL, et al. Acid ceramidase controls apoptosis and increases autophagy in human melanoma cells treated with doxorubicin. Sci Rep 2021;11:1–14.
   PubMed Web of Science ®Google Scholar
• Lai M, Rocca VL, Amato R, et al. Ablation of acid ceramidase impairs autophagy and mitochondria activity in melanoma cells. Int J Mol Sci 2021;22:3247.
   PubMed Web of Science ®Google Scholar
• Scalise V, Sanguinetti C, Neri T, et al. PCSK9 induces tissue factor expression by activation of TLR4/NFkB signaling. Int J Mol Sci 2021;22:12640.
   PubMedGoogle Scholar
• Borgogna C, Bruna R, Griffante G, et al. Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients. Blood Cancer J 2022;12:8–9.
   PubMed Web of Science ®Google Scholar
• Carta A, Bua A, Corona P, et al. Design, synthesis and antitubercular activity of 4-alkoxy-triazoloquinolones able to inhibit the M. tuberculosis DNA gyrase. Eur J Med Chem 2019;161:399–415.
   PubMed Web of Science ®Google Scholar
• Perutz MF, Fermi G, Abraham DJ, et al. Hemoglobin as a drug receptor. J Am Chem Soc 1986;108:1064–78.
   Web of Science ®Google Scholar
• Meyer EA, Castellano RK, Diederich F. Interactions with aromatic rings in chemical and biological recognition. Angew Chem Int Ed Engl 2003;42:1210–50.
   Google Scholar
• Chaitanya GV, Alexander JS, Babu PP. PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun Signal 2010;8:31.
   PubMed Web of Science ®Google Scholar
• Barpe DR, Rosa DD, Froehlich PE. Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass. Eur J Pharm Sci 2010;41:458–63.
   PubMed Web of Science ®Google Scholar